On January 5, 2026 Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, reported that Adam Rosenthal, Ph.D., CEO and Founder, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30 p.m. PT in San Francisco, CA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Rosenthal will provide an overview of the company and its lead program, VGA039, a first-in-class monoclonal antibody therapy that targets Protein S, with dual actions promoting platelet attachment and enhancing fibrin deposition to restore hemostasis. VGA039 has potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, starting with von Willebrand disease (VWD), and is currently being evaluated in a pivotal Phase 3 study for the treatment of VWD. Interim data from the ongoing Phase 1/2 multidose study of VGA039 in VWD were presented at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in December 2025, demonstrating substantial bleed reductions in all patients, across all types of VWD and all types of bleeds.
(Press release, Star Therapeutics, JAN 5, 2026, View Source [SID1234661722])